Strand Therapeutics Raises $45M in Series A1

Strand Therapeutics, a Boston, MA-based programmable mRNA company, raised $45M in Series A1 funding.

The round was led by FPV with participation from Eli Lilly and Company, Potentum Partners, and existing investors Playground Global, and a further unannounced syndicate.

The company intends to use the funds to advance its first drug candidate, a programmable mRNA therapy for solid tumor immuno-oncology into Phase 1 clinical trials next year, to further develop its systemic delivery mechanism, which is designed to deliver tumor microenvironment-modifying mRNA to tumor sites and immune cells, and to expand its multidisciplinary team across biology, bioengineering, bioinformatics, manufacturing, automation, and various G&A functions.

Led by CEO Jake Becraft, Strand Therapeutics is a biotechnology company committed to developing first-in-class programmable mRNA therapeutics. The company has advanced a platform for programmable, long-acting mRNA therapeutics that are bioengineered to enable precise control of the location, timing, intensity, and duration of therapeutic activity. Its mission is to develop improved treatment options for cancer and other life-threatening diseases.